BCX — Bioceltix SA Income Statement
0.000.00%
Last trade - 00:00
- PLN270.48m
- PLN256.10m
2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0.002 | 0.011 | 0 | 0 |
Cost of Revenue | ||||
Gross Profit | -0.41 | -0.468 | -0.854 | -0.7 |
Selling / General / Administrative Expenses | ||||
Depreciation and Amortization | ||||
Unusual Expense / Income | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 1.58 | 2.39 | 4.34 | 8.9 |
Operating Profit | -1.58 | -2.38 | -4.34 | -8.9 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -1.6 | -2.37 | -4.36 | -8.97 |
Provision for Income Taxes | ||||
Net Income After Taxes | -1.6 | -2.35 | -4.4 | -8.92 |
Net Income Before Extraordinary Items | ||||
Net Income | -1.6 | -2.35 | -4.4 | -8.92 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -1.6 | -2.35 | -4.4 | -8.92 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.486 | -0.715 | -1.4 | -2.68 |
Dividends per Share |